SPOTLIGHT -
Calquence and Brukinsa Have Similar Relapsed/Refractory CLL Outcomes
There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.
